Atopic Dermatitis/Atopic Eczema | Unmet Need | Moderate to Severe Topical-Refractory | US/EU | 2021

The approval of Dupixent has transformed the management of topical-refractory moderate to severe atopic dermatitis (AD), and the active, diverse AD pipeline is filled with compelling emerging options from several novel classes including IL-13 inhibitors, JAK inhibitors, and IL-31 inhibitors. In this report, we assess the commercial opportunity remaining in the topical-refractory moderate to severe AD space through a comprehensive analysis of dermatologists’ treatment goals; the key efficacy, safety / tolerability, and delivery attributes driving prescribing choice; the gaps in treatment left by current therapies; and the interplay of clinical and nonclinical attributes in determining the commercial potential of new AD products.

Questions Answered

• What are the key treatment drivers and goals for topical-refractory moderate to severe AD? How do current therapies such as Dupixent perform against these key treatment drivers and goals?
• What are the key opportunities for drug development in topical-refractory moderate to severe AD? Where do surveyed dermatologists perceive the largest gaps in the treatment of topical-refractory moderate to severe AD patients?
• What trade-offs among queried clinical attributes and price are acceptable to U.S. and European dermatologists when considering whether to prescribe a hypothetical new AD therapy?

Content Highlights

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 61 U.S. and 31 European dermatologists fielded in January 2021.

Key companies: Sanofi, Regeneron, LEO Pharma, Eli Lilly, Pfizer, AbbVie, Galderma.

Key drugs: Dupixent, cyclosporine, methotrexate, mycophenolate mofetil, azathioprine, prednisone.

Product Description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.